

Lawrence H Boise

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2125044/lawrence-h-boise-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

236
papers

22,779
citations

53
h-index

150
g-index

250
ext. papers

24,986
ext. citations

5.9
avg, IF

6.15
L-index

#	Paper	IF	Citations
236	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
235	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-546	10.2	2783
234	bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. <i>Cell</i> , 1993 , 74, 597-608	56.2	2712
233	Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. <i>Cell</i> , 1995 , 80, 285-91	56.2	1840
232	CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. <i>Immunity</i> , 1995 , 3, 87-98	32.3	1003
231	Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. <i>Blood</i> , 2006 , 107, 4907-16	2.2	825
230	Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 7834-8	11.5	729
229	Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. <i>BMC Cell Biology</i> , 2013 , 14, 32		564
228	Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 9238-42	11.5	521
227	Bax-independent inhibition of apoptosis by Bcl-XL. <i>Nature</i> , 1996 , 379, 554-6	50.4	454
226	Bcl-XL and Bcl-2 repress a common pathway of cell death. <i>Journal of Experimental Medicine</i> , 1995 , 182, 821-8	16.6	360
225	Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. <i>Cancer Research</i> , 2005 , 65, 11510-9	10.1	271
224	bcl-x is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 4304-8	11.5	245
223	Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. <i>Blood</i> , 2001 , 98, 805-13	2.2	231
222	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. <i>Nature Communications</i> , 2018 , 9, 5341	17.4	227
221	Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 7350-4	11.5	215
220	Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 3759-64	11.5	201

219	Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. <i>Genes and Development</i> , 1996 , 10, 2621-31	12.6	196
218	Regulation of Bcl-xL: a little bit of this and a little bit of STAT. <i>Current Opinion in Oncology</i> , 2000 , 12, 543-9	2.2	188
217	Hierarchical control of lymphocyte survival. <i>Science</i> , 1996 , 274, 67-8	33.3	180
216	Bcl-x(S) antagonizes the protective effects of Bcl-x(L). <i>Journal of Biological Chemistry</i> , 1996 , 271, 6306-12	1.4	155
215	Bcl-2 and Bcl-2-related proteins in apoptosis regulation. <i>Current Topics in Microbiology and Immunology</i> , 1995 , 200, 107-21	3.3	141
214	The role of bcl-XL in CD40-mediated rescue from anti-mu-induced apoptosis in WEHI-231 B lymphoma cells. <i>European Journal of Immunology</i> , 1995 , 25, 1352-7	6.1	136
213	Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. <i>Leukemia</i> , 2014 , 28, 690-3	10.7	135
212	Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 5491-5	11.5	133
211	Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1435-46	16.6	131
210	Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmic reticulum stress-induced apoptosis. <i>Journal of Biological Chemistry</i> , 2005 , 280, 29578-87	5.4	131
209	Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. <i>Clinical Cancer Research</i> , 2002 , 8, 3658-68	12.9	126
208	CD28 and apoptosis. <i>Current Opinion in Immunology</i> , 1995 , 7, 620-5	7.8	123
207	Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. <i>Journal of Biological Chemistry</i> , 2001 , 276, 6320-6	5.4	115
206	Integrin β -mediated regulation of multiple myeloma cell adhesion, migration, and invasion. <i>Blood</i> , 2011 , 117, 6202-13	2.2	104
205	CD28-mediated regulation of multiple myeloma cell proliferation and survival. <i>Blood</i> , 2007 , 109, 5002-10	2.2	98
204	Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. <i>Blood</i> , 2011 , 118, 6368-79	2.2	95
203	Salmonella-induced cell death: apoptosis, necrosis or programmed cell death?. <i>Trends in Microbiology</i> , 2001 , 9, 64-7	12.4	93
202	Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. <i>Blood</i> , 2011 , 118, 1329-39	2.2	92

201	Upstream regulatory role for XIAP in receptor-mediated apoptosis. <i>Molecular and Cellular Biology</i> , 2004 , 24, 7003-14	4.8	92
200	Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. <i>Leukemia</i> , 2016 , 30, 1086-93	10.7	85
199	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. <i>Cell Metabolism</i> , 2017 , 25, 358-373	24.6	83
198	CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. <i>Journal of Immunology</i> , 2000 , 165, 5105-11	5.3	82
197	Potential of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. <i>Blood</i> , 2003 , 101, 2321-7	2.2	79
196	Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. <i>British Journal of Haematology</i> , 2015 , 169, 423-34	4.5	72
195	CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. <i>Journal of Immunology</i> , 2011 , 187, 1243-53	5.3	72
194	BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. <i>Blood</i> , 2008 , 111, 5152-62	2.2	68
193	How I treat high-risk myeloma. <i>Blood</i> , 2015 , 126, 1536-43	2.2	66
192	CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. <i>Blood</i> , 2014 , 123, 3770-9	2.2	60
191	Regulation of T cell activation by CD28 and CTLA4. <i>Advances in Experimental Medicine and Biology</i> , 1996 , 406, 209-17	3.6	60
190	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. <i>Blood</i> , 2014 , 123, 3269-76	2.2	59
189	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019 , 9, 94	7	59
188	Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 259, 67-72	3.4	58
187	Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. <i>Blood</i> , 2017 , 129, 1969-1979	2.2	57
186	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1928-1937	2.2	56
185	Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. <i>Oncogene</i> , 2001 , 20, 7029-40	9.2	55
184	Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. <i>JCI Insight</i> , 2019 , 5,	9.9	55

183	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019 , 10, 1911	17.4	53
182	Cancer Metabolism and the Evasion of Apoptotic Cell Death. <i>Cancers</i> , 2019 , 11,	6.6	50
181	Apoptosis induced by differentiation or serum deprivation in an immortalized central nervous system neuronal cell line. <i>Journal of Neurochemistry</i> , 1996 , 67, 1908-20	6	50
180	Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2019 , 10, 1121	8.4	49
179	MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. <i>Nucleic Acids Research</i> , 2017 , 45, 2396-2407	20.1	48
178	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. <i>Cancer</i> , 2019 , 125, 2991-3000	6.4	47
177	Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. <i>Oncogene</i> , 2016 , 35, 3955-64	9.2	47
176	Ceramide kinase is required for a normal eicosanoid response and the subsequent orderly migration of fibroblasts. <i>Journal of Lipid Research</i> , 2014 , 55, 1298-309	6.3	47
175	KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. <i>Blood</i> , 2012 , 119, 1450-8	2.2	47
174	Mitochondria as targets for established and novel anti-cancer agents. <i>Drug Resistance Updates</i> , 2001 , 4, 85-91	23.2	47
173	Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1197-206	6.1	46
172	Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha. <i>Journal of Biological Chemistry</i> , 2000 , 275, 31546-53	5.4	46
171	CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif. <i>Journal of Immunology</i> , 2015 , 194, 4717-28	5.3	44
170	Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. <i>FEBS Letters</i> , 2017 , 591, 240-251	3.8	44
169	Role of cytochrome C in apoptosis: increased sensitivity to tumor necrosis factor alpha is associated with respiratory defects but not with lack of cytochrome C release. <i>Molecular and Cellular Biology</i> , 2007 , 27, 1771-83	4.8	44
168	Bryostatins enhance paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. <i>Leukemia</i> , 1999 , 13, 1564-73	10.7	44
167	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. <i>Cancer Cell</i> , 2018 , 34, 315-330.e7	24.3	43
166	Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. <i>Molecular Cancer Therapeutics</i> , 2003 , 2, 1155-64	6.1	43

165	The Tao of myeloma. <i>Blood</i> , 2014 , 124, 1873-9	2.2	42
164	Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. <i>Leukemia</i> , 2009 , 23, 2181-3	10.7	41
163	Regulation of RelB expression during the initiation of dendritic cell differentiation. <i>Molecular and Cellular Biology</i> , 2005 , 25, 7900-16	4.8	37
162	Protein kinase C beta11 plays an essential role in dendritic cell differentiation and autoregulates its own expression. <i>Journal of Biological Chemistry</i> , 2005 , 280, 28412-23	5.4	37
161	Potential of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). <i>Biochemical Pharmacology</i> , 2000 , 60, 1445-56	6	37
160	Elevated expression of Bcl-2 and Bcl-x by intestinal intraepithelial lymphocytes: resistance to apoptosis by glucocorticoids and irradiation. <i>International Immunology</i> , 1997 , 9, 945-53	4.9	35
159	Caspase-9 and effector caspases have sequential and distinct effects on mitochondria. <i>Oncogene</i> , 2005 , 24, 6354-66	9.2	35
158	Bcl-2 and caspase inhibition cooperate to inhibit tumor necrosis factor-alpha-induced cell death in a Bcl-2 cleavage-independent fashion. <i>Journal of Biological Chemistry</i> , 1999 , 274, 18552-8	5.4	35
157	When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. <i>Molecular Cancer Research</i> , 2015 , 13, 1163-73	6.6	34
156	Speciation, formation, stability and analytical challenges of human arsenic metabolites. <i>Journal of Analytical Atomic Spectrometry</i> , 2009 , 24, 1397-1405	3.7	34
155	Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. <i>Cancer</i> , 2013 , 119, 4119-28	6.4	33
154	Bcl-xL protein protects from C/EBP homologous protein (CHOP)-dependent apoptosis during plasma cell differentiation. <i>Journal of Biological Chemistry</i> , 2014 , 289, 23629-40	5.4	33
153	Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. <i>Journal of Biological Chemistry</i> , 2009 , 284, 12886-95	5.4	33
152	The prodomain of caspase-3 regulates its own removal and caspase activation. <i>Cell Death Discovery</i> , 2019 , 5, 56	6.9	32
151	Arsenic trioxide in multiple myeloma: rationale and future directions. <i>Cancer Journal (Sudbury, Mass)</i> , 2002 , 8, 12-25	2.2	30
150	R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 179-86	6.1	29
149	Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016 , 1009-1010, 55-65	3.2	26
148	Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 418-427	7.1	25

147	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. <i>Nature Communications</i> , 2020 , 11, 1228	17.4	24
146	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , 2019 , 125, 416-423	6.4	22
145	Procaspase-3 regulates fibronectin secretion and influences adhesion, migration and survival independently of catalytic function. <i>Journal of Cell Science</i> , 2014 , 127, 2217-26	5.3	21
144	Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. <i>Leukemia</i> , 2019 , 33, 1291-1296	10.7	20
143	Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. <i>Blood</i> , 2010 , 116, 5285-8	2.2	20
142	Dimethylarsinothiyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to Darinaparsin. <i>Chemical Research in Toxicology</i> , 2014 , 27, 754-64	4	19
141	Receptors that regulate T-cell susceptibility to apoptotic cell death. <i>Annals of the New York Academy of Sciences</i> , 1995 , 766, 70-80	6.5	19
140	Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. <i>Nature Communications</i> , 2021 , 12, 1714	17.4	19
139	HMG-CoA synthase 1 is a synthetic lethal partner of BRAF in human cancers. <i>Journal of Biological Chemistry</i> , 2017 , 292, 10142-10152	5.4	18
138	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. <i>Oncotarget</i> , 2016 , 7, 59727-59741	3.3	18
137	N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. <i>Leukemia and Lymphoma</i> , 2005 , 46, 899-908	1.9	17
136	Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma. <i>Cancer Informatics</i> , 2014 , 13, 49-53	2.4	16
135	A MCP1 fusokine with CCR2-specific tumoricidal activity. <i>Molecular Cancer</i> , 2011 , 10, 121	42.1	16
134	High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 129-40	3.5	16
133	Interleukin 2-mediated uncoupling of T cell receptor alpha/beta from CD3 signaling. <i>Journal of Experimental Medicine</i> , 1998 , 188, 1575-86	16.6	16
132	Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. <i>Leukemia and Lymphoma</i> , 2003 , 44, 2123-34	1.9	15
131	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. <i>Oncotarget</i> , 2016 , 7, 27753-63	3.3	15
130	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. <i>Cell Reports</i> , 2021 , 34, 108532	10.6	15

129	In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells. <i>Biochemical Pharmacology</i> , 1991 , 42, 853-67 ⁶		14
128	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 332-344	2	13
127	Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals. <i>Journal of Clinical Immunology</i> , 1997 , 17, 234-46	5.7	13
126	TGF- β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. <i>Theranostics</i> , 2020 , 10, 7656-7670	12.1	13
125	Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF- κ B pathway. <i>International Journal of Cancer</i> , 2015 , 136, 2341-51	7.5	12
124	Molecular impact of selective NF κ B1 and NF κ B2 signaling on DLBCL phenotype. <i>Oncogene</i> , 2017 , 36, 4224-4232	9.2	11
123	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2016 , 17, 769-77	4.6	11
122	Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2139-2139	2.2	11
121	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021 , 137, 3604-3615	2.2	11
120	Extraction tool and matrix effects on arsenic speciation analysis in cell lines. <i>Analytica Chimica Acta</i> , 2011 , 699, 187-92	6.6	10
119	Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019 , 134, 926-926	2.2	10
118	Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. <i>PLoS ONE</i> , 2012 , 7, e52662	3.7	10
117	CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell Survival. <i>Cell Reports</i> , 2020 , 31, 107815	10.6	10
116	Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia. <i>Oncogene</i> , 2016 , 35, 479-90	9.2	9
115	Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. <i>Nucleic Acids Research</i> , 2016 , 44, e69	20.1	9
114	CD86 regulates myeloma cell survival. <i>Blood Advances</i> , 2017 , 1, 2307-2319	7.8	9
113	Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 3214-3227	7.8	9
112	Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma. <i>Cancer Research</i> , 2019 , 79, 2102-2103	10.1	8

111	14-3-3 β binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. <i>Leukemia</i> , 2018 , 32, 744-751	10.7	8
110	Introduction of the cell survival gene bcl-xL improves the viability of CTLL-2 cells without affecting their IL-2 proliferative response. Implications for the development of bioassays. <i>Journal of Immunological Methods</i> , 1996 , 191, 143-8	2.5	8
109	Components of intrinsic drug resistance in the rat hepatoma. <i>Biochemical Pharmacology</i> , 1992 , 43, 331-40		8
108	The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. <i>Leukemia Research</i> , 2012 , 36, 784-90	2.7	7
107	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020 , 10, 40	7	7
106	Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming. <i>FEBS Journal</i> , 2018 , 285, 2626-2640	9.7	7
105	The future of drug development and therapy in myeloma. <i>Seminars in Oncology</i> , 2013 , 40, 652-8	5.5	6
104	Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis. <i>Cell Death and Differentiation</i> , 1997 , 4, 294-303	12.7	6
103	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. <i>Blood</i> , 2013 , 122, 3135-3135	2.2	6
102	Game of Bones: How Myeloma Manipulates Its Microenvironment. <i>Frontiers in Oncology</i> , 2020 , 10, 625199	9.3	5
101	Potential application of SERS for arsenic speciation in biological matrices. <i>Analytical and Bioanalytical Chemistry</i> , 2017 , 409, 4683-4695	4.4	4
100	Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons. <i>Autophagy</i> , 2011 , 7, 448-9	10.2	4
99	Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients. <i>Blood</i> , 2019 , 134, 572-572	2.2	4
98	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. <i>Blood</i> , 2011 , 118, 1855-1855	2.2	4
97	Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. <i>Oncology</i> , 2011 , 25 Suppl 2, 25-31	1.8	4
96	DUB-ling down on B-cell malignancies. <i>Blood</i> , 2015 , 125, 3522-3	2.2	3
95	Cloning and analysis of Bcl-2 family genes. <i>Methods in Cell Biology</i> , 2001 , 66, 29-47	1.8	3
94	Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 952-952	2.2	3

93	Downregulation of PA28 α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 125	7	3
92	Oncolytic herpes simplex virus infects myeloma cells and. <i>Molecular Therapy - Oncolytics</i> , 2021 , 20, 519-584	5.4	3
91	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019 , 125, 185-193	6.4	3
90	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021 , 96, E68-E71	7.1	3
89	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. <i>Journal of Oncology Practice</i> , 2018 , 14, 561-564	3.1	3
88	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. <i>Cancers</i> , 2021 , 13,	6.6	3
87	Aiming at WM with both barrels blocked. <i>Blood</i> , 2010 , 115, 4007-8	2.2	2
86	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , 2018 , 132, 3282-3282	2.2	2
85	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018 , 132, 3294-3294	2.2	2
84	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 5647-5647	2.2	2
83	Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma. <i>Blood</i> , 2019 , 134, 4407-4407	2.2	2
82	Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).. <i>Blood</i> , 2006 , 108, 1966-1966	2.2	2
81	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs).. <i>Blood</i> , 2011 , 118, 3994-3994	2.2	2
80	Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry. <i>Blood</i> , 2012 , 120, 2072-2072	2.2	2
79	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1924-1924	2.2	2
78	Efficacy Of ABT-199 In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 4453-4453	2.2	2
77	B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2108-2108	2.2	2
76	Bcl-xL Protects From UPR-Associated Apoptosis During Plasma Cell Differentiation. <i>Blood</i> , 2012 , 120, 3288-3288	2.2	2

75	BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 11-24	2.6	2
74	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021 , 2, 600-615	7	2
73	To Gli or not to Gli. <i>Blood</i> , 2014 , 124, 2008-9	2.2	1
72	TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. <i>Blood Advances</i> , 2017 , 1, 1848-1853	7.8	1
71	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018 , 132, 3241-3241	2.2	1
70	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. <i>Blood</i> , 2018 , 132, 1884-1884	2.2	1
69	In Vitro Activity of a Novel Organic Arsenical (S-Dimethylarsino-Glutathione, ZIO-101) Against Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 5163-5163	2.2	1
68	The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.. <i>Blood</i> , 2009 , 114, 1689-1689	2.2	1
67	Targeting the CD28-B7 Pro-Survival Pathway In Multiple Myeloma. <i>Blood</i> , 2010 , 116, 132-132	2.2	1
66	Impact of Body Mass Index (BMI) On Overall Survival in Myeloma. <i>Blood</i> , 2012 , 120, 4289-4289	2.2	1
65	Mir-155 Expression Raises the Apoptotic Threshold in Waldenström Macroglobulinemia By Inhibition of FOXO3a and Bim. <i>Blood</i> , 2014 , 124, 1671-1671	2.2	1
64	Vorinostat, Bortezomib, Cyclophosphamide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2014 , 124, 5773-5773	2.2	1
63	Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). <i>Blood</i> , 2015 , 126, 5344-5344	2.2	1
62	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8540-8540	2.2	1
61	Multiple myeloma immunoglobulin λ translocations portend poor prognosis		1
60	Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease. <i>Blood</i> , 2019 , 134, 858-858	2.2	1
59	Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple Myeloma		1
58	Phosphorylation Influences The Binding Of Bim To Anti-Apoptotic Proteins In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 4446-4446	2.2	1

57	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021 , 27, 3178-3189	12.9	1
56	A miRaculous new therapy in myeloma?. <i>Blood</i> , 2018 , 132, 983-985	2.2	1
55	Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function. <i>Blood</i> , 2018 , 132, 951-951	2.2	0
54	Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor,. <i>Blood</i> , 2011 , 118, 3950-3950	2.2	0
53	Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2013 , 41	2.6	
52	Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells. <i>Scientific World Journal, The</i> , 2001 , 1, 110	2.2	
51	Conversion from a Type I to a Type II Death Receptor-Mediated Pathway through A Partial Inhibition of Caspase-8. <i>Scientific World Journal, The</i> , 2001 , 1, 98	2.2	
50	Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma. <i>Blood</i> , 2021 , 138, 1612-1612	2.2	
49	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. <i>Blood</i> , 2021 , 138, 1624-1624	2.2	
48	Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma. <i>Blood</i> , 2021 , 138, 1589-1589	2.2	
47	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1611-1611	2.2	
46	CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival.. <i>Blood</i> , 2005 , 106, 355-355		
45	Glutathione and Glutathione Utilizing Enzymes Are Key Determinants in the Sensitivity of Myeloma Cells to Arsenic Trioxide as Well as Its Mechanism of Action.. <i>Blood</i> , 2005 , 106, 5143-5143	2.2	
44	Gene Profile during Arsenic Trioxide-Induced Apoptosis in Multiple Myeloma: Strong Anti-Oxidantive Response and Pro-Apoptotic Imbalance.. <i>Blood</i> , 2005 , 106, 5175-5175	2.2	
43	S-Dimethylarsinoglutathione (SGLU/ZIO101) Is a Novel Active Organic Arsenical That Displays a Unique Gene Expression Profile in Myeloma Cells.. <i>Blood</i> , 2006 , 108, 5043-5043	2.2	
42	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , 2018 , 132, 3302-3302	2.2	
41	Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy. <i>Blood</i> , 2018 , 132, 405-405	2.2	
40	Whole Genome DNA Methylation Analysis of Compass Identifies Biomarkers of Multiple Myeloma Survival. <i>Blood</i> , 2018 , 132, 3174-3174	2.2	

- 39 A Role for Syntenin-1 in Multiple Myeloma Cell Survival. *Blood*, **2018**, 132, 1008-1008 2.2
- 38 The Role of Proteasome Activator PA28 in Multiple Myeloma. *Blood*, **2019**, 134, 5499-5499 2.2
- 37 Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degradors of Oncoproteins. *Blood*, **2019**, 134, 3183-3188
- 36 Detection of NFKB2 End Loops By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma. *Blood*, **2014**, 124, 2138-2138²
- 35 Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma. *Blood*, **2014**, 124, 3447-3447 2.2
- 34 Risk Factors for Development of Myeloma: Role of Smoking and Alcohol. *Blood*, **2014**, 124, 2604-2604 2.2
- 33 Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells. *Blood*, **2014**, 124, 4726-4726 2.2
- 32 Induction of Bim-Dependent and -Independent Apoptosis in Multiple Myeloma. *Blood*, **2014**, 124, 4716-4716
- 31 Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT). *Blood*, **2015**, 126, 4202-4202 2.2
- 30 Small Molecule Bcl-2 Inhibitor Bcl-2 BH4 Antagonist for Multiple Myeloma Therapy. *Blood*, **2015**, 126, 2049-2049
- 29 Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant. *Blood*, **2016**, 128, 4524-4524 2.2
- 28 Bak Binding to Bcl-xL and Not to Mcl-1 Is Associated with ABT-737 Sensitivity in Multiple Myeloma Cell Lines. *Blood*, **2008**, 112, 3675-3675 2.2
- 27 Displacement of Bim From Anti-Apoptotic Proteins Is the Primary Factor for Determining ABT-737 Activity in Multiple Myeloma Cell Lines. *Blood*, **2009**, 114, 2851-2851 2.2
- 26 Distribution of Bim Determines MCL-1 Dependence or Co-Dependence on BCL-xL/BCL-2 In Multiple Myeloma. *Blood*, **2010**, 116, 4054-4054 2.2
- 25 Long Term Humoral Immunity Is Dependent on CD28 Expression In Plasma Cells. *Blood*, **2010**, 116, 1737-1737
- 24 A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials. *Blood*, **2011**, 118, 3954-3954 2.2
- 23 Sustained Antibody Responses Depend on CD28 Function in Bone Marrow Resident Plasma Cells. *Blood*, **2011**, 118, 182-182 2.2
- 22 Prosurvival and Immunosuppressive Functions of CD28 in the Myeloma Tumor Microenvironment. *Blood*, **2011**, 118, 473-473 2.2

21	Truncation of NF- κ B2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2891-2891	2.2
20	ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2884-2884	2.2
19	Validation of the Function of 14-3-3 σ In Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 1369-1369	2.2
18	MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells. <i>Blood</i> , 2011 , 118, 1870-1870	2.2
17	Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets.. <i>Blood</i> , 2012 , 120, 2953-2953	2.2
16	CD28 and CD86 Are Necessary for Myeloma Cell Survival.. <i>Blood</i> , 2012 , 120, 2946-2946	2.2
15	Integrative, Multi-Platform, Whole-Genome Analyses Identify Clinically Relevant Common- and Cell-Specific Signatures in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 3974-3974	2.2
14	Targeting the Cellular and Molecular Components of CD28 Mediated Survival Signaling in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 722-722	2.2
13	Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins. <i>Blood</i> , 2012 , 120, 4024-4024	2.2
12	TGR-1202: A Novel, Targeted PI3K γ Inhibitor in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 5018-5018	2.2
11	The Role of 14-3-3 σ In Regulation of Proteasome Inhibitor Bortezomib Sensitivity in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1845-1845	2.2
10	CD28 and CD86 Regulate Integrin Surface Expression In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 4450-4450	2.2
9	Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT). <i>Blood</i> , 2013 , 122, 5606-5606	2.2
8	Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample. <i>Blood</i> , 2013 , 122, 5582-5582	2.2
7	Combined Carfilzomib and Selective PI3K γ Inhibition (TGR1202) Results In Enhanced Myeloma Cell Apoptosis. <i>Blood</i> , 2013 , 122, 3224-3224	2.2
6	P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1929-1929	2.2
5	Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC). <i>Blood</i> , 2013 , 122, 3148-3148	2.2
4	Heterogeneous Bcl-2 Family Expression In Waldenström Macroglobulinemia Determines Response To Inducers Of Intrinsic Apoptosis. <i>Blood</i> , 2013 , 122, 4287-4287	2.2

- 3 Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma. *Blood*, **2013**, 122, 3171-3171 2.2
- 2 Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma. *Blood*, **2013**, 122, 1856-1856 2.2
- 1 Myeloma's sound of silencing. *Blood*, **2019**, 134, 1116-1117 2.2